Key result
Aspirin withdrawal at 90 days cuts major bleeding ~38% without excess myocardial infarction risk.
Why the study?
Trials of P2Y12 inhibitor monotherapy after PCI withdrew aspirin at fixed times mostly against 12-month DAPT, and categorical syntheses disagree on the safe minimum duration of DAPT before aspirin withdrawal.
Does shorter duration of dual antiplatelet therapy before aspirin withdrawal with P2Y12 inhibitor continuation affect 12-month myocardial infarction and major bleeding compared to 12-month DAPT in patients undergoing PCI?
Meta-Analysis (n=58,068)
Does shorter duration of dual antiplatelet therapy before aspirin withdrawal with P2Y12 inhibitor continuation affect 12-month myocardial infarction and major bleeding compared to 12-month DAPT in patients undergoing PCI?
In patients undergoing PCI, shorter DAPT before transitioning to P2Y12 inhibitor monotherapy reduces major bleeding, while a 15% excess risk of myocardial infarction can only be excluded after approximately 5 to 9 months of DAPT rather than at a 1-month threshold.
Answers are grounded in this paper and cite their sources.
MI risk not significantly increased with aspirin withdrawal; extends support for P2Y12 monotherapy but leaves optimal duration open.
Background: Trials of P2Y12 inhibitor monotherapy after percutaneous coronary intervention (PCI) withdrew aspirin at fixed times, mostly against 12-month dual antiplatelet therapy (DAPT), and categorical syntheses disagree. Methods: Bayesian model-based network meta-analysis of randomized trials of aspirin withdrawal with P2Y12 inhibitor continuation, with 12-month myocardial infarction (MI) and major bleeding modeled as functions of DAPT duration (Emax and spline). The prespecified estimand was the shortest duration at which the upper 95% credible limit of the odds ratio (OR) for MI versus 12-month DAPT fell below 1.15. Results: Sixteen trials (17 randomized comparisons, 58,068 patients) contributed 929 MIs and 1,102 major bleeding events. The OR for MI was 1.31 (95% credible interval 0.95–2.09) at 0 days, 1.17 (0.96–1.43) at 30 days, and 1.09 (0.98–1.25) at 90 days. Under every model the point estimate exceeded 1.15 below about 3 weeks and fell below it from about 90 days; a 30-day change-point did not fit better. The credible bound was met at 158 days (Emax) and 282 days (spline). Bleeding decreased with shorter duration (OR 0.40 at 0 days, 0.62 at 90 days). Certainty was low for MI below 90 days and the estimand, moderate for bleeding. Conclusions: Shorter DAPT reduced major bleeding, and the ischemic cost of aspirin withdrawal declined with duration; a step at 1 month was not supported. A 15% excess of MI could be excluded from about 5 months (Emax) or 9 months (spline). The curves match duration to each patient's ischemic margin.
No takes yet. Share an insight, caveat, or question.
Jang et al. (2026) conducted a meta-analysis in Percutaneous coronary intervention (PCI) (n=58,068). Short-duration dual antiplatelet therapy (DAPT) followed by aspirin withdrawal and P2Y12 inhibitor continuation vs. 12-month dual antiplatelet therapy (DAPT) was evaluated on 12-month myocardial infarction (MI) and major bleeding; prespecified estimand was shortest DAPT duration with upper 95% credible limit of MI OR <1.15 vs 12-month DAPT (OR 1.17 at 30 days; OR 1.09 at 90 days, 95% CI 0.96-1.43 at 30 days; 0.98-1.25 at 90 days). Shorter DAPT before aspirin withdrawal reduced major bleeding, while a 15% excess of MI vs 12-month DAPT was excluded from 158 days (Emax) or 282 days (spline).
Synapse has enriched 10 related papers. Consider them for comparative context: